The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Suspension of Trading

17 Oct 2016 07:00

Onzima Ventures Plc - Suspension of Trading

Onzima Ventures Plc - Suspension of Trading

PR Newswire

London, October 14

Onzima Ventures PLC

("Onzima" or the "Company")

Suspension of Trading

On 14 October 2015, following a general meeting and approval of all resolutions by shareholders, Onzima became an Investing Company under the AIM Rules for Companies and adopted a new Investing Policy. Over the last 12 months, the Company has assessed a large number of investments and invested in 19 companies, as well as evaluated a number of potential reverse takeover opportunities.

As an Investing Company, the Company is required to implement its Investing Policy within 12 months or make an acquisition or acquisitions which constitute a reverse takeover under the AIM Rules, failing which the Company's ordinary shares would be suspended from trading on AIM. However, as at today's date, the Company has not made an acquisition or acquisitions which constitute a reverse takeover under the AIM Rules or otherwise implemented its Investing Policy to the satisfaction of the London Stock Exchange. Accordingly, in accordance with Rule 15 of the AIM Rules for Companies, the Company’s ordinary shares will be suspended from trading with effect from 7:30 am today.

In the event that the Company is deemed to have implemented its Investing Policy, the Company will apply for the suspension to be lifted. Pending the implementation of its Investing Policy or completion of a reverse takeover, trading in the Company’s ordinary shares will remain suspended.

If the Company has not made an acquisition or acquisitions which constitute a reverse takeover under the AIM Rules or otherwise implemented its Investing Policy within 6 months of the suspension, being 17 April 2017, the admission of the Company's ordinary shares to AIM will be cancelled.

For further information please contact:

Onzima Ventures PLC Tel: +44 (0) 1732 366 561

Gavin Burnell, Luke Cairns

Nominated Adviser

Cairn Financial Advisers LLP Tel: +44 (0) 20 7213 0170

Sandy Jamieson, Liam Murray

Broker

Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930 

Guy Miller, Lucy Williams

Date   Source Headline
29th Apr 202410:59 amRNSPosting of Annual Report & Notice of AGM
26th Apr 20247:00 amRNSN4 Pharma Webinar on SRI Collaboration
25th Apr 20247:38 amRNSCollaboration Agreement with SRI International Inc
23rd Apr 20247:00 amRNSFinal Results
18th Apr 20247:00 amRNSOral Delivery Update
4th Mar 20243:13 pmRNSHolding(s) in Company
29th Feb 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSin-vitro siRNA update
19th Jan 20247:00 amRNSPatent Grant
18th Jan 202410:15 amRNSHolding(s) in Company
16th Jan 20247:00 amRNSNanogenics Update
8th Jan 20244:24 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSAAV Viral Vector Update
18th Dec 20237:00 amRNSOral Delivery Update
7th Dec 202311:28 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSNuvec® R&D and Strategy Update
30th Nov 20239:00 amRNSN4 Pharma Launches New Interactive Investor Hub
31st Oct 20237:00 amRNSTotal Voting Rights
9th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
3rd Oct 20238:15 amRNSHolding(s) in Company
2nd Oct 20237:00 amRNSInvestor Presentation
28th Sep 20237:00 amRNSAcquisition of Controlling Interest in Nanogenics
12th Sep 20237:00 amRNSInterim Results
25th Jul 20237:00 amRNSPatent Grant and Board Change
27th Jun 20237:00 amRNSGrant Award for Professor Chengzhong Yu
25th Apr 20237:00 amRNSsiRNA update
18th Apr 20237:00 amRNSsiRNA update
3rd Apr 20232:11 pmRNSResult of AGM
9th Mar 20237:00 amRNSPosting of Annual Report & Notice of AGM
9th Mar 20237:00 amRNSFinal Results
14th Feb 20234:40 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSOral application update
30th Nov 20225:28 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSTotal Voting Rights
25th Nov 20222:49 pmRNSHolding(s) in Company
22nd Nov 202210:50 amRNSResult of Broker Offer and Total Voting Rights
18th Nov 20227:01 amRNSBroker Offer to raise a maximum of £1 million
18th Nov 20227:00 amRNSPlacing to raise £1million and Broker Offer
1st Nov 20227:00 amRNSPatent filing update
4th Oct 20227:00 amRNSDouble siRNA Testing Update
29th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOperational Update
15th Jul 20227:00 amRNSWork Programme Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.